Naotoshi Sugimoto
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 149 publications
Phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (WJOG10517G), including an individual patient data comparison with JCOG1108/WJOG7312G.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: April 28, 2026
Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
Long-term survival outcomes from a phase II trial of perioperative capecitabine plus oxaliplatin for advanced gastric cancer with extensive lymph node metastases: OGSG 1701.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: December 12, 2025
Chronic theobromine administration attenuates short-term memory decline via neurotrophic, anti-inflammatory and antioxidant mechanisms in senescence-accelerated mouse prone 8 (SAMP8).
Journal: The Journal of nutritional biochemistry
Published: November 01, 2025
Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan.
Journal: EClinicalMedicine
Published: October 11, 2025
Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study.
Journal: Japanese journal of clinical oncology
Published: September 03, 2025
Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
Journal: International journal of clinical oncology
Published: June 24, 2025
Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment.
Journal: Cancer reports (Hoboken, N.J.)
Published: May 18, 2025
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 16, 2025
Clinical and prognostic characteristics of metastatic colorectal cancer with minor RAS mutations.
Journal: Oncology letters
Published: March 17, 2025
First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study.
Journal: International journal of clinical oncology
Published: March 12, 2025
Last Updated: 09/26/2026